The global Digital Biomarkers Market was valued at $5.84 billion in 2025 and is projected to reach $24.88 billion by 2033, with a CAGR of 19.89%. The U.S. market was valued at $1.89 billion in 2025 and is projected to reach $7.86 billion by 2033, growing at a CAGR of 19.49%. Demand is driven by chronic diseases, AI, and machine learning integration.
Regulatory agencies like the FDA and EMA are offering frameworks to support digital biomarkers in clinical trials. Major players include Apple, Google, Microsoft, Samsung, and Fitbit. By deployment mode, cloud-based solutions hold the largest share, while physiological biomarkers dominate the market. Neurology applications lead in usage, while wearables are the preferred platform.
In recent news, Apple Watch received FDA clearance for a hypertension detection feature, and Verily launched the Numetric Watch for real-time biomarker data capture in clinical trials. North America leads the digital biomarkers market, while Asia Pacific is the fastest-growing region, driven by healthcare digitalization and AI platforms. The Digital Biomarkers Market Report provides exclusive insights into adoption and usage statistics, clinical trial integration, technology adoption rate, healthcare impact metrics, security and privacy benchmarks, and competitive landscape analysis. The market is projected to reach USD 24.88 billion by 2033 with a CAGR of 19.89% from 2026 to 2033. Key segments include biomarker type, application, platform, deployment mode, end user, and distribution channel across various regions globally.
The report highlights the global and regional uptake of digital biomarker solutions, wearable device usage, and health app penetration, offering insights into consumer and patient engagement trends in connected healthcare ecosystems. It also showcases the growing use of digital biomarkers in Phase II/III clinical trials, demonstrating reductions in trial timelines and validation rates through cloud-based infrastructure.
An analysis of technology adoption rate includes deployment models, the role of AI in biomarker-based monitoring, and FDA/EMA-cleared solutions, identifying innovation and investment hotspots. Healthcare impact metrics assess real-world outcomes like improved patient adherence, reduced hospital readmissions, and enhanced remote monitoring capabilities driven by IoT-enabled biomarker technologies.
The report also addresses security and privacy benchmarks to understand key challenges faced by healthcare providers regarding data security, compliance, and patient privacy, crucial for evaluating vendor readiness and trust levels. Additionally, it provides a competitive landscape overview of leading IaaS and PaaS vendors, their strengths, partnerships, product portfolios, and growth strategies, enabling stakeholders to benchmark technological leadership and market positioning.
Read more at GlobeNewswire: Global Digital Biomarkers Market Set to Reach USD 24.88